59 related articles for article (PubMed ID: 30557403)
1. Nucleophosmin in leukemia: Consequences of anchor loss.
Brodská B; Šašinková M; Kuželová K
Int J Biochem Cell Biol; 2019 Jun; 111():52-62. PubMed ID: 31009764
[TBL] [Abstract][Full Text] [Related]
2. FLT3 ligand plasma levels in acute myeloid leukemia.
Peterlin P; Gaschet J; Guillaume T; Garnier A; Eveillard M; Le Bourgeois A; Cherel M; Debord C; Le Bris Y; Theisen O; Mahé B; Dubruille V; Godon C; Robillard N; Wuilleme S; Touzeau C; Gastinne T; Blin N; Lok A; Bonnet A; Le Gouill S; Moreau P; Béné MC; Chevallier P
Haematologica; 2019 Jun; 104(6):e240-e243. PubMed ID: 30630980
[No Abstract] [Full Text] [Related]
3. Single cell analysis of clonal architecture in acute myeloid leukaemia.
Potter N; Miraki-Moud F; Ermini L; Titley I; Vijayaraghavan G; Papaemmanuil E; Campbell P; Gribben J; Taussig D; Greaves M
Leukemia; 2019 May; 33(5):1113-1123. PubMed ID: 30568172
[TBL] [Abstract][Full Text] [Related]
4. Blast phenotype and comutations in acute myeloid leukemia with mutated NPM1 influence disease biology and outcome.
Mason EF; Hasserjian RP; Aggarwal N; Seegmiller AC; Pozdnyakova O
Blood Adv; 2019 Nov; 3(21):3322-3332. PubMed ID: 31698462
[TBL] [Abstract][Full Text] [Related]
5. Targeting and Monitoring Acute Myeloid Leukaemia with Nucleophosmin-1 (
Chin L; Wong CYG; Gill H
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834572
[TBL] [Abstract][Full Text] [Related]
6. Current status and future perspectives in targeted therapy of NPM1-mutated AML.
Ranieri R; Pianigiani G; Sciabolacci S; Perriello VM; Marra A; Cardinali V; Pierangeli S; Milano F; Gionfriddo I; Brunetti L; Martelli MP; Falini B
Leukemia; 2022 Oct; 36(10):2351-2367. PubMed ID: 36008542
[TBL] [Abstract][Full Text] [Related]
7.
Kuželová K; Brodská B; Marková J; Petráčková M; Schetelig J; Ransdorfová Š; Gašová Z; Šálek C
Oncoimmunology; 2022; 11(1):2073050. PubMed ID: 35558161
[TBL] [Abstract][Full Text] [Related]
8. Neoantigen-Specific T-Cell Immune Responses: The Paradigm of NPM1-Mutated Acute Myeloid Leukemia.
Forghieri F; Riva G; Lagreca I; Barozzi P; Bettelli F; Paolini A; Nasillo V; Lusenti B; Pioli V; Giusti D; Gilioli A; Colasante C; Galassi L; Catellani H; Donatelli F; Talami A; Maffei R; Martinelli S; Potenza L; Marasca R; Tagliafico E; Manfredini R; Trenti T; Comoli P; Luppi M
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502069
[TBL] [Abstract][Full Text] [Related]
9. NSC348884 cytotoxicity is not mediated by inhibition of nucleophosmin oligomerization.
Šašinková M; Heřman P; Holoubek A; Strachotová D; Otevřelová P; Grebeňová D; Kuželová K; Brodská B
Sci Rep; 2021 Jan; 11(1):1084. PubMed ID: 33441774
[TBL] [Abstract][Full Text] [Related]
10. High PD-L1 Expression Predicts for Worse Outcome of Leukemia Patients with Concomitant
Brodská B; Otevřelová P; Šálek C; Fuchs O; Gašová Z; Kuželová K
Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31185600
[TBL] [Abstract][Full Text] [Related]
11. Antigen Targets for the Development of Immunotherapies in Leukemia.
Bauer J; Nelde A; Bilich T; Walz JS
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30897713
[TBL] [Abstract][Full Text] [Related]
12. Altered HLA Class I Profile Associated with Type A/D Nucleophosmin Mutation Points to Possible Anti-Nucleophosmin Immune Response in Acute Myeloid Leukemia.
Kuželová K; Brodská B; Fuchs O; Dobrovolná M; Soukup P; Cetkovský P
PLoS One; 2015; 10(5):e0127637. PubMed ID: 25992555
[TBL] [Abstract][Full Text] [Related]
13. Mutated nucleophosmin detects clonal multilineage involvement in acute myeloid leukemia: Impact on WHO classification.
Pasqualucci L; Liso A; Martelli MP; Bolli N; Pacini R; Tabarrini A; Carini M; Bigerna B; Pucciarini A; Mannucci R; Nicoletti I; Tiacci E; Meloni G; Specchia G; Cantore N; Di Raimondo F; Pileri S; Mecucci C; Mandelli F; Martelli MF; Falini B
Blood; 2006 Dec; 108(13):4146-55. PubMed ID: 16926285
[TBL] [Abstract][Full Text] [Related]
14. Cytoplasmic expression of nucleophosmin accurately predicts mutation in the nucleophosmin gene in patients with acute myeloid leukemia and normal karyotype.
Luo J; Qi C; Xu W; Kamel-Reid S; Brandwein J; Chang H
Am J Clin Pathol; 2010 Jan; 133(1):34-40. PubMed ID: 20023256
[TBL] [Abstract][Full Text] [Related]
15. Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications.
Falini B; Bolli N; Liso A; Martelli MP; Mannucci R; Pileri S; Nicoletti I
Leukemia; 2009 Oct; 23(10):1731-43. PubMed ID: 19516275
[TBL] [Abstract][Full Text] [Related]
16. Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias.
Falini B; Nicoletti I; Bolli N; Martelli MP; Liso A; Gorello P; Mandelli F; Mecucci C; Martelli MF
Haematologica; 2007 Apr; 92(4):519-32. PubMed ID: 17488663
[TBL] [Abstract][Full Text] [Related]
17. Association of HLA class I type with prevalence and outcome of patients with acute myeloid leukemia and mutated nucleophosmin.
Kuželová K; Brodská B; Schetelig J; Röllig C; Ráčil Z; Walz JS; Helbig G; Fuchs O; Vraná M; Pecherková P; Šálek C; Mayer J
PLoS One; 2018; 13(12):e0204290. PubMed ID: 30557403
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
